Screener
Adaptive Biotechnologies ADPT Sales & Marketing
Sales & Marketing at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Cost of revenue | 18,708 | 16,979 |
| Research and development | 23,623 | 24,203 |
| Sales and marketing | 26,346 | 23,047 |
| General and administrative | 20,984 | 17,399 |
| Amortization of intangible assets | 419 | 419 |
| Total operating expenses | 90,080 | 82,047 |
| Loss from operations | (19,206) | (29,604) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's sales & marketing?
- Adaptive Biotechnologies (ADPT) reported sales & marketing of $26.35M in Q1 2026.
- How has Adaptive Biotechnologies's sales & marketing changed year-over-year?
- Adaptive Biotechnologies's sales & marketing increased by 14.3% year-over-year, from $23.05M to $26.35M.
- What is the long-term trend for Adaptive Biotechnologies's sales & marketing?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's sales & marketing has grown at a -0.2% compound annual growth rate (CAGR), from $95.47M to $94.57M.
- What does sales & marketing mean?
- Costs of selling products and services including sales force compensation, commissions, marketing campaigns, trade shows, and customer acquisition expenses.
Ask your AI about Adaptive Biotechnologies's sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude